Published in Neuroimage on January 27, 2011
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. JAMA Neurol (2015) 3.58
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.91
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Diagnostic neuroimaging across diseases. Neuroimage (2011) 1.66
Applying tensor-based morphometry to parametric surfaces can improve MRI-based disease diagnosis. Neuroimage (2013) 1.17
Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun (2013) 1.15
2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. PLoS One (2011) 1.14
Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol (2013) 1.10
Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med (2012) 1.02
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun (2014) 1.01
Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer's disease. Cereb Cortex (2012) 1.01
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry. Neuroimage (2014) 0.97
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav (2012) 0.96
The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer's disease. IEEE/ACM Trans Comput Biol Bioinform (2013) 0.94
Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology (2013) 0.91
Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. Diabetes (2015) 0.90
Early indications of future cognitive decline: stable versus declining controls. PLoS One (2013) 0.89
Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data. Alzheimers Dement (2014) 0.87
Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol Aging (2011) 0.86
Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement (2013) 0.86
A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative. Biol Psychiatry (2013) 0.86
Recent advances in imaging Alzheimer's disease. J Alzheimers Dis (2013) 0.85
Association between an Alzheimer's Disease-Related Index and APOE ε4 Gene Dose. PLoS One (2013) 0.84
Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Dis Assoc Disord (2015) 0.80
Multimodal neuroimaging computing: the workflows, methods, and platforms. Brain Inform (2015) 0.80
Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. Eur J Nucl Med Mol Imaging (2013) 0.80
Translational research in neurology: dementia. Arch Neurol (2012) 0.79
Neuroimaging of dementia in 2013: what radiologists need to know. Eur Radiol (2013) 0.79
Short-Term Practice Effects and Brain Hypometabolism: Preliminary Data from an FDG PET Study. Arch Clin Neuropsychol (2015) 0.78
Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings. Neurology (2015) 0.78
Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. ScientificWorldJournal (2013) 0.78
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement (2015) 0.78
Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline. Eur J Nucl Med Mol Imaging (2017) 0.76
Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression. PLoS One (2016) 0.75
Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model. Front Hum Neurosci (2017) 0.75
Cross-View Neuroimage Pattern Analysis in Alzheimer's Disease Staging. Front Aging Neurosci (2016) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 8.36
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol (2000) 3.99
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain (2007) 3.53
Volumetric transformation of brain anatomy. IEEE Trans Med Imaging (1997) 3.51
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res (2009) 3.31
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry (2002) 3.20
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage (2010) 2.32
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology (1998) 2.24
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation. Neuroimage (2010) 2.04
Prevalence of dementia after age 90: results from the 90+ study. Neurology (2008) 1.88
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology (2008) 1.80
Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus (2009) 1.65
Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.53
Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging (2010) 1.21
Normalization in PET group comparison studies--the importance of a valid reference region. Neuroimage (2008) 1.12
Subcortical elevation of metabolism in Parkinson's disease--a critical reappraisal in the context of global mean normalization. Neuroimage (2009) 1.07
Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res (2008) 1.06
Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. Neuroimage (2009) 1.03
The effect of brain atrophy on cerebral hypometabolism in the visual variant of Alzheimer disease. Arch Neurol (2001) 1.01
Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging (2010) 1.01
Apolipoprotein E genotype and early Alzheimer's disease: a longitudinal SPECT study. J Neuroimaging (2003) 0.82
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A (2004) 17.86
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Mapping cortical change across the human life span. Nat Neurosci (2003) 8.98
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
Longitudinal mapping of cortical thickness and brain growth in normal children. J Neurosci (2004) 7.30
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Sexual dimorphism of brain developmental trajectories during childhood and adolescence. Neuroimage (2007) 5.86
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
Mapping brain asymmetry. Nat Rev Neurosci (2003) 4.99
Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science (2003) 4.72
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage (2010) 4.28
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07